Psychiatr. pro Praxi, 2009; 10(4): 163-166

Prediction of treatment outcome in schizophrenia

MUDr. Tomáš Kašpárek Ph.D
Psychiatrická klinika LF MU a FN Brno

Schizophrenia is a condition with highly variable outcome. In clinical practice we need to answer questions about the course of the illness

in particular patients. Current evidence suggests that clinical picture, co-morbid conditions, duration of untreated psychosis, subjective

evaluation of the treatment, time-course of treatment response are all important in the outcome prediction. An open question remains

if it will be possible to use objective markers for prediction.

Keywords: schizophrenia, prediction, treatment, remission, outcome.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kašpárek T. Prediction of treatment outcome in schizophrenia. Psychiatr. praxi. 2009;10(4):163-166.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ceskova E, Prikryl R, Kasparek T, Ondrusova M. Psychopathology and treatment responsiveness of patients with first-episode schizophrenia. Neuropsychiatr Dis Treat 2005; 1: 179-185. Go to original source... Go to PubMed...
    2. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatric Clinics of North America 2003; 26: 115-139. Go to original source... Go to PubMed...
    3. Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM. Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophrenia Research 2003; 61: 89-95. Go to original source... Go to PubMed...
    4. Ulas H, Alptekin K, Akdede BB, Tumuklu M, Akvardar Y, Kitis A, Polat S. Panic symptoms in schizophrenia: Comorbidity and clinical correlates. Psychiatry and Clinical Neurosciences 2007; 61: 678-680. Go to original source... Go to PubMed...
    5. Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 2005; 75: 349-362. Go to original source... Go to PubMed...
    6. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35 Suppl: S93-100. Go to original source... Go to PubMed...
    7. Jager M, Riedel M, Schmauss M, Pfeiffer H, Laux G, Naber D, Gaebel W, Huff W, Schmidt LG, Heuser I, Buchkremer G, Kuhn KU, Ruther E, Hoff P, Gastpar M, Bottlender R, Strauss A, Moller HJ. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Res 2008; 158: 297-305. Go to original source... Go to PubMed...
    8. Sim K, Chua TH, Chan YH, Mahendran R, Chong SA. Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study. J Psychiatr Res 2006; 40: 656-663. Go to original source... Go to PubMed...
    9. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in 1st-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188. Go to original source... Go to PubMed...
    10. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. American Journal of Psychiatry 1996; 153: 519-525. Go to original source... Go to PubMed...
    11. Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. Journal of Psychiatric Research 1998; 32: 151-159. Go to original source... Go to PubMed...
    12. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis - Pathways to care. British Journal of Psychiatry 1998; 172: 45-52. Go to original source...
    13. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 2003; 160: 2063-2065. Go to original source... Go to PubMed...
    14. Chang YC, Lane HY, Yang KH, Huang CL. Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 2006; 26: 554-559. Go to original source... Go to PubMed...
    15. Leucht S, Busch R, Kissfing W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 352-360. Go to original source... Go to PubMed...
    16. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, KollackWalker S, Sniadecki JL, Kane JM. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 2008; 102: 230-240. Go to original source... Go to PubMed...
    17. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. American Journal of Psychiatry 2006; 163: 743-745. Go to original source...
    18. Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985; 30: 246-248. Go to original source... Go to PubMed...
    19. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - Concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36: S181-S190. Go to original source... Go to PubMed...
    20. Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999; 156: 544-549. Go to original source... Go to PubMed...
    21. Ceskova E, Drybcak P, Hrobar P, Lorenc M, Prochazkova H, Spacek J. The changes of biological markers and treatment efficacy in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2001; 25: 323-335. Go to original source... Go to PubMed...
    22. de Haan L, van Nimwegen L, van Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, A 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008; 41: 125-128. Go to original source... Go to PubMed...
    23. Jager M, Riedel M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Moller HJ. Prediction of symptom remission in schizophrenia during inpatient treatment. World J Biol Psychiatry 2007: 1-9.
    24. Oosthuizen P, Emsley R, Niehaus D, Koen L, Chiliza B. The relationships between depression and remission in first-episode psychosis. World Psychiatry 2006; 5: 172-176.
    25. Novick D, Haro JM, Suarez D, Lambert M, Lepine JP, Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology 2007; 191: 1015-1022. Go to original source... Go to PubMed...
    26. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophrenia Research 2007; 95: 19-29. Go to original source... Go to PubMed...
    27. Nuechterlein KH, Dawson ME, Ventura J, Gitlin M, Subotnik KL, Snyder KS, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand Suppl 1994; 382: 58-64. Go to original source... Go to PubMed...
    28. Xiang YQ, Zhang ZJ, Weng YZ, Zhai YM, Li WB, Cai ZJ, Tan QR, Wang CY. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophrenia Research 2006; 83: 201-210. Go to original source... Go to PubMed...
    29. Haro JM, Novick D, Suarez D, Ochoa S, Roca M. Predictors of the course of illness in outpatients with schizophrenia: A prospective three year study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008; 32: 1287-1292. Go to original source... Go to PubMed...
    30. Black K, Peters L, Rui Q, Milliken H, Whitehorn D, Kopala LC. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophrenia Research 2001; 47: 215-222. Go to original source... Go to PubMed...
    31. Barnes TRE, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. British Journal of Psychiatry 2008; 193: 203-209. Go to original source... Go to PubMed...
    32. Ropcke B, Eggers C. Early-onset schizophrenia. European Child & Adolescent Psychiatry 2005; 14: 341-350. Go to original source... Go to PubMed...
    33. Stricker K, Schulze Monking H, Buchkremer G. Family interaction and the course of schizophrenic illness. Results of a multivariate prospective study. Psychopathology 1997; 30: 282-290. Go to original source... Go to PubMed...
    34. Dickerson FB, Stallings C, Origoni A, Boronow JJ, Sullens A, Yolken R. Predictors of occupational status six months after hospitalization in persons with a recent onset of psychosis. Psychiatry Research 2008; 160: 278-284. Go to original source... Go to PubMed...
    35. Mueser KT, Salyers MP, Mueser PR. A prospective analysis of work in schizophrenia. Schizophr Bull 2001; 27: 281-296. Go to original source... Go to PubMed...
    36. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163: 418-425. Go to original source... Go to PubMed...
    37. Prikryl R, Ceskova E, Kasparek T, Kucerova H. Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. J Psychiatr Res 2006; 40: 141-146. Go to original source... Go to PubMed...
    38. Wolwer W, Brinkmeyer J, Riesbeck M, Freimuller L, Klimke A, Wagner M, Moller HJ, Klingberg S, Gaebel W. Neuropsychological impairments predict the clinical course in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008; 258 Suppl 5: 28-34. Go to original source... Go to PubMed...
    39. Mitelman SA, Shihabuddin L, Brickman AM, Hazlett EA, Buchsbaum MS. Volume of the cingulate and outcome in schizophrenia. Schizophr Res 2005; 72: 91-108. Go to original source... Go to PubMed...
    40. Prasad KM, Sahni SD, Rohm BR, Keshavan MS. Dorsolateral prefrontal cortex morphology and short-term outcome in firstepisode schizophrenia. Psychiatry Res 2005; 140: 147-155. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.